Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
May 12, 2016 4:05 PM EDTLOS ANGELES, May 12, 2016 /PRNewswire/ --Â Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the first quarter ended March 31, 2016 as well as a business update.
"The first quarter was a productive start to this year on both the clinical and financial fronts for Capricor. We had two positive developments in our lead CAP-1002 development programsfirst, reducing the enrollment goal of the Phase II ALLSTAR... More
